Switch theme
Sign up to access all valuation multiples
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
2007
61
LTM Revenue $7.8M
LTM EBITDA n/a
-$29.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BioAtla has a last 12-month revenue of $7.8M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, BioAtla achieved revenue of $11.0M and an EBITDA of -$73.0M.
BioAtla expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BioAtla valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $11.0M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$128M | -$73.0M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -664% | XXX | XXX | XXX |
| Net Profit | -$106M | -$123M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -1122% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, BioAtla's stock price is $0.
BioAtla has current market cap of $18.4M, and EV of -$29.8M.
See BioAtla trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$29.8M | $18.4M | XXX | XXX | XXX | XXX | $-1.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, BioAtla has market cap of $18.4M and EV of -$29.8M.
BioAtla's trades at -3.8x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate BioAtla's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for BioAtla and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$29.8M | XXX | XXX | XXX |
| EV/Revenue | -2.7x | XXX | XXX | XXX |
| EV/EBITDA | 0.4x | XXX | XXX | XXX |
| P/E | -0.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBioAtla's NTM/LTM revenue growth is -100%
BioAtla's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $1.4M for the same period.
Over next 12 months, BioAtla's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate BioAtla's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for BioAtla and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -664% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -43% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 199% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 574% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 772% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioAtla acquired XXX companies to date.
Last acquisition by BioAtla was XXXXXXXX, XXXXX XXXXX XXXXXX . BioAtla acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was BioAtla founded? | BioAtla was founded in 2007. |
| Where is BioAtla headquartered? | BioAtla is headquartered in United States of America. |
| How many employees does BioAtla have? | As of today, BioAtla has 61 employees. |
| Who is the CEO of BioAtla? | BioAtla's CEO is Dr. Jay M. Short,PhD. |
| Is BioAtla publicy listed? | Yes, BioAtla is a public company listed on NAS. |
| What is the stock symbol of BioAtla? | BioAtla trades under BCAB ticker. |
| When did BioAtla go public? | BioAtla went public in 2020. |
| Who are competitors of BioAtla? | Similar companies to BioAtla include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of BioAtla? | BioAtla's current market cap is $18.4M |
| What is the current revenue of BioAtla? | BioAtla's last 12-month revenue is $7.8M. |
| What is the current EV/Revenue multiple of BioAtla? | Current revenue multiple of BioAtla is -3.8x. |
| Is BioAtla profitable? | Yes, BioAtla is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
